You are here: Industry Insights > CAR-T

News List

Cancer-Fighting CAR-T Cell Immunotherapy Potentially Induces New Cancers: An Analysis of Potential Safety Challenges Big Cat of Medical Field
March 06, 2024
Recent reports have indicated that the National Medical Products Administration has addressed the potential carcinogenicity associated with CAR-T cell immunotherapy.
Domestic Enterprises Have Fully Laid out the Blue Ocean of US$10 Billion, and CAR-T Therapy Must Overcome the Achilles' Heel of Solid Tumor 203 Spuer/PharmaSources
August 07, 2023
The solid tumor is one of the two most deeply developed fields in CAR-T therapy, thus it is extremely urgent to overcome solid tumor in CAR-T therapy, considering domestic market access policy and current biomedical capital environment.
Research progress of dual-target CAR-T in China from the perspective of the ASCO 2023 Xiaobin/PharmaSources
June 27, 2023
At the ASCO this year, Gracell Bio announced the long-term follow-up data of its multi-center clinical study of CAR-T therapy with GC012F for recurrent/refractory multiple myeloma (R/R MM) in the form of oral report at the annual meeting.
With Sky-high Price, CAR-T Therapy Sold at Least USD1.709 Billion in 2021 PharmaSources/Yi
March 30, 2022
Currently, six CART-cell immunotherapies have been approved in China and abroad, as shown in the table below. Except for Abecma, the other five therapies are all targeted at CD19.
Going Global Successfully! BCMA CAR-T of Legend Biotech is Approved by FDA for Marketing! PharmaSources/Small pill
March 16, 2022
On February 28 local time, LEGN.US officially announced in Somerset, New Jersey, U.S., that its self-developed BCMA-targeted CAR-T therapy, ciltacabtagene autoleucel (trade name: CARVYKTI®), abbreviated as Cilta-cel, was approved for marketing by the FDA.
The Second CAR-T Therapy in China Applied for Marketing PharmaSources/Dopine
July 01, 2020
On June 30, according to the official website of CDE, the marketing application of a CAR-T therapy, JWCAR029 by JW Therapeutics was accepted by CDE.
Cell Therapy Expected to Treat Solid Tumors in the Future as a CAR-T cell Therapy Clinical Trial for Treating Gastric and Pancreatic Cancers was Accepted PharmaSources/Xiaobin
June 17, 2020
CAR-T cells can be easily led to cancer cells by relying on this target, to wipe out cancer. However, there is no such apparent target that only exists in tumor cells instead of normal cells in solid tumors.
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen AmericanPharmaceuticalReview
February 15, 2022
Legend Biotech Corporation has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel)...
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent prnasia
February 14, 2022
IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, and Innovent Biologics, Inc.
Curocell, Breaks Ground on 'CAR-T Manufacturing GMP Facility' prnasia
December 24, 2021
Curocell, currently on PhaseⅠCAR-T Therapy clinical trial with CRC01 (anbalcabtagene autoleucel) has recently broken ground for the new CAR-T Center in Dungok Residential & Industrial Area in Daejeon International Science & Business Belt.